Early molecular layer interneuron hyperactivity triggers Purkinje neuron degeneration in SCA1
F Pilotto, C Douthwaite, R Diab, XQ Ye, C Tietje… - Neuron, 2023 - cell.com
Toxic proteinaceous deposits and alterations in excitability and activity levels characterize
vulnerable neuronal populations in neurodegenerative diseases. Using in vivo two-photon …
vulnerable neuronal populations in neurodegenerative diseases. Using in vivo two-photon …
Morphological and functional principles governing the plasticity reserve in the cerebellum: the cortico-deep cerebellar nuclei loop model
Simple Summary We propose a more comprehensive scheme underlying cerebellar
reserve. Under pathological conditions, the internal forward model continuously updates …
reserve. Under pathological conditions, the internal forward model continuously updates …
[HTML][HTML] The pathogenetic basis for a disease continuum in early-and late-onset ataxia-dystonia supports a unified genetic diagnostic approach
M Garofalo, F Vansenne, DS Verbeek… - European Journal of …, 2023 - Elsevier
Introduction Genetically inherited ataxic disorders are classified by their age of disease
presentation into early-and late-onset ataxia (EOA and LOA, presenting before or after the …
presentation into early-and late-onset ataxia (EOA and LOA, presenting before or after the …
[HTML][HTML] Memantine suppresses the excitotoxicity but fails to rescue the ataxic phenotype in SCA1 model mice
OS Belozor, A Vasilev, AG Mileiko, LD Mosina… - Biomedicine & …, 2024 - Elsevier
Abstract Spinocerebellar ataxia type 1 (SCA1) is a debilitating neurodegenerative disorder
of the cerebellum and brainstem. Memantine has been proposed as a potential treatment for …
of the cerebellum and brainstem. Memantine has been proposed as a potential treatment for …
3, 5-Dimethyladamantan-1-amine Restores Short-term Synaptic Plasticity by Changing Function of Excitatory Amino Acid Transporters in Mouse Model of …
OS Belozor, AA Vasilev, AG Mileiko… - Annals of clinical …, 2024 - annaly-nevrologii.com
Introduction. Memantine is an agent that used for treatment of Alzheimer's type dementia.
Memantine considerably reduces the effects of neurodegeneration, may potentially slow …
Memantine considerably reduces the effects of neurodegeneration, may potentially slow …
3, 5-диметил-адамантан-1-амин восстанавливает кратковременную синаптическую пластичность посредством изменения функции транспортёров …
ОС Белозор, АА Васильев, АГ Милейко… - Анналы клинической и …, 2024 - elibrary.ru
Введение. Мемантин-препарат для лечения деменции альцгеймерского типа, который
значительно уменьшает явления нейродегенерации. Потенциально он может …
значительно уменьшает явления нейродегенерации. Потенциально он может …